Delsie Braganza

Delsie joined the Focal Point Research team in 2011 and has been an invaluable asset for our clients. With her strong regulatory and quality assurance background, she is able to help clients understand the Canadian and US requirements, set targets to achieve compliance, and attain their goals to get products to market.

Delsie is able to audit facilities, set up and maintain GMP compliant facilities, develop strong quality management systems, and co-ordinate successful Health Canada inspections. In addition to this, Delsie oversees all regulatory compliance reviews and submissions made to Health Canada and the US FDA.

Delsie obtained an Honours Bachelor of Science (Hons. B. Sc.) in Pharmaceutical Chemistry from the University of Toronto, Post-Graduate Certificate in Pharmaceutical Regulatory Affairs and Quality Operations (RAQ) from Seneca College and Regulatory Affairs Certification (RAC) from the Regulatory Affairs Professional Society (RAPS).

When she’s not learning something new, Delsie loves spending time with family, going on road trips or long walks, and swimming.

Articles

If you would like to be added to our newsletter, please send an email to mail@focalpointresearch.net with the subject line ‘Receive FPR Newsletter’.

California bill targets ‘Reel Safe’ Sunscreen Claims

Oct 13, 2026

California AB 1744 would prohibit sunscreen manufacturers and sellers from marketing products as 'reel safe', 'reel friendly', 'ocean safe', 'marine safe' or similar terms unless the sunscreen contains no chemical ultraviolet filters. The bill specifically identifies...

Washington State Department of Ecology Updates Interim Policy on Lead in Cosmetics

Oct 13, 2026

The Washington State Department of Ecology (Ecology) has released substantial updates to its Interim Policy on Lead in Cosmetics. The revisions eliminate the sunset date for the interim enforcement framework and introduce an active audit mechanism through a mandatory...

FDA Implements Split Payment Framework for FY 2027 OTC Monograph Facility Fees

Oct 13, 2026

The U.S. Food and Drug Administration (FDA) has established a two-part installment plan for Fiscal Year (FY) 2027 Over-the-Counter (OTC) monograph drug facility user fees. Under this payment schedule, regulated drug establishments must remit their annual facility fees...

First Amendment Milestone: Federal Court Bars California Prop 65 Cancer Warnings for Diethanolamine (DEA)

Oct 13, 2026

In a landmark decision for cosmetic and personal care manufacturers, a federal court in Sacramento has permanently prohibited the State of California from enforcing Proposition 65 cancer warning mandates for products containing the common surfactant diethanolamine...

FDA issues warning letters to OTC companies over talc testing

Oct 13, 2026

In June 2026, the FDA issued nine warning letters to OTC companies over products containing talc, citing concerns about potential asbestos contamination. The letters identified cGMP deficiencies involving ingredient and finished product testing, supplier...

FDA Warning Letter Trends

Oct 13, 2026

Recent FDA warning letters to topical OTC manufacturers continue to highlight familiar GMP deficiencies, with supplier oversight and analytical testing emerging as recurring areas of focus. In an August warning letter, the FDA emphasized that companies remain...

Streamlining Post-Market Vigilance: Health Canada Overhauls Guidance on Notifying Foreign Regulatory Actions

Oct 13, 2026

Health Canada has announced a modernized regulatory framework governing how Market Authorization Holders (MAHs) report safety actions and restrictions occurring in international jurisdictions. Officially taking effect on October 1, 2026, the revised guidance...

Health Canada Updates Summary Reporting Guidance for Marketed Drugs and Natural Health Products

Oct 13, 2026

Health Canada has announced an updated version of its foundational guidance, Preparing and Submitting Summary Reports for Marketed Drugs and Natural Health Products - Guidance Document for Industry, officially entering into force on October 1, 2026. Replacing the...

Reminder: Upcoming Health Canada Medical Device Licence Renewal Deadline

Oct 13, 2026

Manufacturers of licensed Class II, III and IV medical devices marketed in Canada are reminded that the annual Medical Device Licence (MDL) renewal deadline is November 1, 2026. Manufacturers must submit the required renewal information to Health Canada before this...

ICCR: E-labelling and Digital Information General Principles

Sep 9, 2026

ICCR has published a guide regarding e-labelling and digital information general principles. Through the ICCR, global regulators have established a set of general principles designed to foster globally compatible approaches to digital cosmetic labelling. The digital...

« Older Entries

“Focal Point Research has consistently and professionally looked after regulatory and quality issues of our brand for years. Through a courteous and knowledgeable team, they have managed to navigate us through an ever changing regulatory landscape while maintaining our interests, and allowed us to correctly distribute and sell within Canada.”

“I have truly enjoyed working with you over the last 8 years! You and your team have been an amazing resource for me. I have always been impressed by the knowledge and professionalism of everyone at Focal Point, which is a true testament to your leadership.”

Connect With Us

The Focal Point Research team is ready to help with all of your scientific and regulatory needs. Our team has the experience and expertise you need to see your product to market and we are eager to help you.

Focal Point Research Inc.

6700 Century Ave., Suite 319

Mississauga, ON L5N 6A4
(905) 271 2709

Delsie Braganza

Jennifer Porter, BA Psychology, MBA – President & CEO

Articles

If you would like to be added to our newsletter, please send an email to mail@focalpointresearch.net with the subject line ‘Receive FPR Newsletter’.

Connect With Us